WIN 552122

Drug Profile

WIN 552122

Alternative Names: WIN 55212; WIN 55212-2

Latest Information Update: 20 Feb 2006

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sanofi Winthrop
  • Developer Sanofi Winthrop; University of Minnesota
  • Class Antiparkinsonians; Cannabinoids; Neuroprotectants
  • Mechanism of Action Cannabinoid receptor agonists; Cannabinoid receptor CB1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Glaucoma; Movement disorders; Neurological disorders; Pain

Most Recent Events

  • 20 Feb 2006 Discontinued - Preclinical for Glaucoma in USA (Ophthalmic)
  • 20 Feb 2006 Discontinued - Preclinical for Movement disorders in USA (unspecified route)
  • 20 Feb 2006 Discontinued - Preclinical for Neurological disorders in Spain (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top